Skip to main content

Home/ Cancer/ Group items tagged advanced castration-resistant

Rss Feed Group items tagged

Matti Narkia

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms... - 0 views

  •  
    Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
    Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS.
    J Clin Oncol. 2008 Oct 1;26(28):4563-71. Epub 2008 Jul 21.
    PMID: 18645193
    DOI: 10.1200/JCO.2007.15.9749
1 - 1 of 1
Showing 20 items per page